top of page
Systemic Therapeutics Corp. is a Canadian pre-clinical stage, biotechnology company specialized in the development of new therapies focusing on the master regulator of lipid metabolism, sterol regulatory-element binding proteins (SREBP), based on first-in-class small molecule SREBP inhibitors. The Company aims to provide new treatment options for metabolic conditions such as dyslipidemia, via reduction of circulating PCSK9, and Non-Alcoholic Fatty Liver Disease.
We are pioneering a new approach to the care of metabolic disorders
with first-in-class small molecule SREBP inhibitors.
A Novel Paradigm for Metabolic Disorders.
OUR TEAM OF
INDUSTRY LEADERS
Richard C. Austin, BSc MSc PhD
Co-Founder, Executive Chairman and Chief Scientific Officer
Mark Tarnopolsky, MD PhD FRCPC
Co-Founder and Vice President,
Business Development
Guillaume Paré, MD MSc FRCPC
Co-Founder and Chief Medical Officer
Jakob Magolan, PhD
Co-Founder and Vice President,
Drug Discovery
Latest News
bottom of page